CLINICAL_TRIALS
trial_result
· 2017-02-13
Clinical Trial Update: LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research [Phase 3]
Summary
Phase 3 trial LUME-Columbus evaluating nintedanib plus docetaxel in advanced non-small cell lung cancer was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2017-02-13